|
Pulmonary Emphysema
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Alpha-1 antitrypsin deficiency (AATD) results from mutations in the SERPINA1 gene and classically presents with early-onset emphysema and liver disease.
|
21752289 |
2011 |
|
Pulmonary Emphysema
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Individuals with an alpha 1-AT deficiency are at an increased risk of developing emphysema.
|
1893597 |
1991 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
alpha(1)-Antitrypsin (AT) deficiency is a hereditary disorder that may lead to early-onset emphysema, and chronic liver disease later in life.
|
20436173 |
2010 |
|
Pulmonary Emphysema
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Reduced serum levels of alpha-1-antitrypsin may be a common factor of emphysema and HS.
|
28712697 |
2017 |
|
Pulmonary Emphysema
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The recommended standard dose (SD; 60 mg/kg/wk) elevates AAT trough serum levels to around 50% of normal; however, outside of slowing emphysema progression, its effects in other clinical outcomes have not been rigorously proven.<b>Objectives:</b> To evaluate the biological effects of normalizing AAT trough levels with double-dose (DD) therapy (120 mg/kg/wk) in subjects with AATD already receiving SD therapy.<b>Methods:</b> Clinically stable subjects were evaluated after 4 weeks of SD therapy, followed by 4 weeks of DD therapy, and 4 weeks after return to SD therapy.
|
30965011 |
2019 |
|
Pulmonary Emphysema
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Molecular characterisation of three alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) nullcardiff (Asp256----Val); PiMmalton (Phe51----deletion) and PiI (Arg39----Cys).
|
2606478 |
1989 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
This provides an explanation for at least some of the observed variation in the development of emphysema in A1AT deficient subjects.
|
12753532 |
2003 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
The rationale of α1-antitrypsin (AAT) augmentation therapy to treat progressive emphysema in AAT-deficient patients is based on inhibition of neutrophil elastase; however, the benefit of this treatment remains unclear.
|
23975926 |
2013 |
|
Pulmonary Emphysema
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
The deficient alpha-I-antitrypsin phenotype PI P is associated with an A-to-T transversion in exon III of the gene.
|
2787118 |
1989 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our hypothesis is based on the fact that danazol is administered in the treatment of pulmonary emphysema because it stimulates synthesis of alpha-1 antitrypsin and that other estrogen glucuro-conjugated metabolites are P-glycoprotein substrates.
|
9360432 |
1997 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using this material, five individuals with severe serum alpha 1-antitrypsin deficiency (PiZ phenotype) and advanced emphysema received 4 g of alpha 1-antitrypsin intravenously at weekly intervals for four doses.
|
7028785 |
1981 |
|
Pulmonary Emphysema
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Null alpha1-antitrypsin (alpha1AT) alleles represent the end of a continuum of variants associated with profound alpha1AT deficiency and an increased risk of emphysema.
|
9070606 |
1997 |
|
Pulmonary Emphysema
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Homozygous inheritance of the Z-type mutant form of the alpha 1-antitrypsin (alpha 1AT) gene results in the most common form of alpha 1AT deficiency, a human hereditary disease associated with a high risk for the development of emphysema and an increased incidence of neonatal hepatitis.
|
2904702 |
1988 |
|
Pulmonary Emphysema
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Patients with acquired emphysema, associated with cigarette smoking, have normal levels of alpha 1-AT in their lungs.
|
1320328 |
1992 |
|
Pulmonary Emphysema
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
DNA restriction fragments associated with alpha 1-antitrypsin indicate a single origin for deficiency allele PI Z.
|
2989709 |
1985 |
|
Pulmonary Emphysema
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
MVarallo: a new M(Like) alpha 1-antitrypsin-deficient allele.
|
14639110 |
2003 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
Six and twelve weeks of anti-AAT oligonucleotide therapy induced emphysema that was worse in female than male mice: mean linear intercept 73.4 versus 62.5 μm (<i>P</i> = 0.000003).
|
31017014 |
2019 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
The putative protective serum concentration is generally considered to be above a threshold of 11 μM/L, and therapeutic augmentation of AAT above this value is believed to retard the progression of emphysema.
|
28769553 |
2017 |
|
Pulmonary Emphysema
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The Z mutation (E342K) of α1-antitrypsin (α1-AT), carried by 4% of Northern Europeans, predisposes to early onset of emphysema due to decreased functional α1-AT in the lung and to liver cirrhosis due to accumulation of polymers in hepatocytes.
|
27246852 |
2016 |
|
Pulmonary Emphysema
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure.
|
2254451 |
1990 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
The resulting lack of circulating α(1)-antitrypsin predisposes the Z homozygote to proteolytic lung damage and emphysema.
|
21966212 |
2011 |
|
Pulmonary Emphysema
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Only 12 cases of alpha 1-AT deficiency have been reported in Japan, including five cases in which the genetic defects have already been elucidated: Mnichinan (delta Phe52[TTC] and Gly148[GGG]-->Arg148[AGG]), two unrelated cases of Siiyama (Ser53[TCC]-->Phe53[TTC]), a heterozygote of Mmalton (delta Phe52[TTC]), and one additional case of 14q- syndrome (sporadic deletion of the neighboring region of the alpha 1-AT gene locus). alpha 1-AT Siiyama is a deficient variant originally identified in a 38-yr-old patient with pulmonary emphysema in Japan.
|
8520784 |
1995 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
The administration of periodic infusions of AAT is the only specific treatment for delaying the progression of emphysema associated with AATD.
|
25027067 |
2015 |
|
Pulmonary Emphysema
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genetic deficiency of alpha 1-antitrypsin in man is a predisposing factor to emphysema and a disorder potentially correctable by somatic gene therapy.
|
3502102 |
1987 |
|
Pulmonary Emphysema
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
It is well known that homozygous deficiency of alpha(1)-antitrypsin, PiZZ, is associated with an increased risk of emphysema.
|
18263681 |
2008 |